Dr.Elizabeth Jacobs, MD/MAPP, Healthcare Research and Policy, MaineHealth
Dr. Liz is the Associate Chair for Research, Department of Internal Medicine at Dell Medical, and VP for Research at MaineHealth, a not-for-profit family of high-quality providers and health care organizations in Maine recognized as one of the US's top integrated health care delivery networks. Dr. Liz previously served as Chief of Primary Care at Dell and prior to joining Dell Medical School, she was a professor of medicine and population health sciences and vice chair for health services research in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health.
Dr. Jacobs’ research interests include access to, and cultural specificity of, medical care delivered to patients, the impact of interpreter service interventions on the cost and quality of healthcare, health literacy, and numeracy, and the role that trust in health care plays in racial/ethnic disparities in health care. Her research has been supported by grants from the National Cancer Institute, the National Institute on Aging, The Robert Wood Johnson Foundation, The California Endowment, The Russell Sage Foundation, The Patient-Centered Outcomes Research Institute, and the Office of Minority Health.
She has served on the Office of Minority Health, Joint Commission, National Quality Forum, Patient-Centered Outcomes Research Institute, and AHRQ expert panels. She received the Chancellor's Community-Academic Partnership Award, 2017, University of Wisconsin System; Outstanding Investigator Award, 2017 School of Medicine and Public Health, University of Wisconsin, and Addis Costello Award, 2014, American College of Physicians Wisconsin Chapter. She attended medical school at the University of California at San Francisco and trained as a general internist at Brigham and Women’s Hospital in Boston. She completed a Robert Wood Johnson Clinical Scholars fellowship and a master’s in public policy at the University of Chicago.
Richard J Siemens
His Excellency Marwan Bin Jassim Al Sarkal
His Excellency Marwan bin Jassim Al Sarkal is the Executive Chairman of the Sharjah Investment and Development Authority (Shurooq), an entity tasked with leading the continued transformation and economic diversification of the emirate of Sharjah. Named as the Middle East CEO by the prestigious Burj CEO Awards and chosen as one of '100 most Powerful Arabs' by Arabian Business magazine, HE Marwan is one of the key business leaders in the UAE to drive and lead the investment and cultural growth of Sharjah. His career with Shurooq began as CEO of the authority in 2009 at the time of its establishment under an Emiri decree by His Highness Sheikh Dr. Sultan bin Muhammad Al Qasimi, Member of the Supreme Council and Ruler of Sharjah. HE Marwan bin Jassim Al Sarkal has played an integral role in transforming Sharjah's economic infrastructure, diversifying markets, and facilitating new investments by major developments covering environment, healthcare, logistics, tourism, light manufacturing, education, real estate, aquaculture, agriculture, mobility, and AI. He has spearheaded major infrastructural projects and key partnerships at Shurooq estimated at a total value of more than AED 10 billion.
His creative, innovative thinking and futuristic approach, rooted in the emirate's traditions and history, have enabled Shurooq to adopt world-class standards. With his exceptional commitment to diversity, training, gender inclusivity, and continuous learning, Marwan has enabled an open, creative, and innovative environment that designs projects for future generations. He is also a board member of several organizations and has won countless accolades including the FDI Environmentally Sustainable Developments Industry during the European CEO Awards.
An avid traveler and technology enthusiast, HE Marwan bin Jassim Al Sarkal holds a BAS in Accounting and Business Administration.
Life Sciences Chair, Foley Hoag
Recognized by Massachusetts Lawyers Weekly as Top Women and inducted into the LMG Life Sciences Hall of Fame, Hemmie is Chair of Foley Hoag's Licensing & Strategic Alliances Practice and Co-Chair of the Life Sciences Group. She brings in a strategic business perspective and legal acumen of two-plus decades of experience within the biopharmaceutical, medical device, gene and cell therapy, and genomics sectors. Hemmie has closed more than $12 billion in deals in recent years across diverse therapeutic areas with all leading pharma players globally. Her representations include Dicerna (NASDAQ; DRNA)'s $200+ million research collaboration with Boehringer Ingelheim for GalXC RNAi therapeutics; Korean pharma Dong-A ST in a $525 million exclusive license opposite AbbVie for a Mer Tyrosine Kinase inhibitor; and Genomics Medicine Ireland in an AbbVie Ireland partnership with WuXi NexCODE Genomics for population genomics research in Ireland. Hemmie is a frequent speaker on BIO and LES panels, teaches the "How to Create Value from Inventions" seminar as part of the Harvard Business School New Venture Competition, and served as a mentor for MassBio, MassChallenge and North Shore InnoVentures companies.
In addition to a long history of community and civic involvement, Chang has worked on pro bono matters for the Asian American Legal Defense and Education Fund (AALDEF). Most recently, she has advised AALDEF on their efforts to support universities defending race-conscious admissions policies, and contributed to amicus briefs in support of affirmative action policies that detractors claim are discriminatory. Hemmie also serves as a Director and Secretary for the South Cove Manor nursing home founded in Boston’s Chinatown and a Director of the Franklin Square House Foundation, which serves homeless women and children in the Greater Boston area.
Leo B. Womack Family Trust
Leo has served as a Houston business leader for 30+ years and owns Ramsey Financial Group (RFG), a Texas-based single-family office established since 1992. RFG seeks to preserve wealth, deploy capital into the most viable, long-term, wealth-building opportunities that have good risk-to-reward metrics. Portfolio industries include public and private companies in space tech, real estate, life sciences, medical devices, agri-tech, and more. Leo started his career with Arthur Anderson to buy a CPA firm in Texas Medical Centre that grew into a large private CPA firm to finally merge it with Fox & Co to be the partner in Houston. Meanwhile, he had co-founded the 376-bed Park Plaza Hospital with 140 physician partners, and a surgery center company that built 12 centers regionally to sell it to an NYSE Hospital Management company for over $100mn. He is the chairman at Monebo, Artella (previously CorVitals), patented Mobile Cardiac Telemetry (MCT) for EKGs. He also is a board member for Eden Grow Systems, an agri-tech firm, the SpaceTech Fund, and more. Leo co-founded Gulf Equities Realty Advisors and is a co-founder of the Houston Angel Network, the most active and oldest angel network in the US with over $400M in 100 companies to foster innovation and entrepreneurship.
Leo's close associate running BCMT at Baylor, Steve Banks got Leo into Fairway Medical Technologies to grow the practice. FMT is a business to design, develop, manufacture, and commercialize medical devices and technologies. Steve broke ground in investments with Henry Hillman in the '70s particularly in biopharma deals such as Genentech or HybriTech (acquired by Lilly).
Co-founder, MD, Hughes Systique Corp.
Mr Vinod Sood is Co-Founder and Managing Director at Hughes Systique Corporation (HSC), an Engineering R&D Solutions & Services company. He is also on the Board of Hughes Communications India. Prior to his current role, he was Head of Global Engineering and R&D at Hughes Software Systems (HSS) and served on its Board as well. HSC is a signatory to the UN Women and UN Global Compact’s Women’s Empowerment Principles (“WEPs”).
Vinod is a veteran of hi-tech software industry, during his career span of 36 years he has built high performance teams at premier R&D organizations in India. Vinod has an exceptional track record of building profitable and sustainable institutions from conceptualization to maturity. Before HSS, Vinod worked with C-DOT where he was part of the core team which designed India 1st Digital Switch. He is member of NASSCOM Engineering R&D Council and Chair of Northern Regional Council. Established in 1988, NASSCOM, a not-for-profit industry association, is the apex body for the 194 billion dollar IT BPM industry in India, an industry that had made a phenomenal contribution to India's GDP, exports, employment, infrastructure and global visibility.
Vinod is a member of Advisory Committee of the Institute of Informatics and Communications, University of Delhi, Shoolini University Solan, KR Mangalam University, BML Munjal University and Masters Union Business School Gurugram. Vinod is involved in guiding and mentoring young entrepreneurs and startups and is on the Advisory Boards of some of these startups. He is a TiE Charter member and is part of several CII, NASSCOM, and TiE juries to identify emerging startups and innovative product companies. An alumnus of PEC Chandigarh from where Vinod graduated with a Gold Medal.
Dr. Neil Campbell,
Board, Life Sciences Pennsylvania
A global C-level entrepreneurial executive with 25+ years of success building public and private businesses in science & technology sectors with a strong focus on the life sciences through the commercialization of over 290 products and services. Neil started his career with Abbot Labs, IGEN (Now Roche) and spent an executive career with private VC/PE international investment fund experience as a general partner and advisor and has advised HNWI, FOs, VC, and PE funds with board practice advisory services and helped build start-ups to Fortune 500 providing leadership in turnarounds, stagnant growth, emerging-growth, and developing country. Dr. Campbell runs Mosaigen, founded in 2004 as a global technology development corporation specializing in the life sciences, ICT, and Cleantech industries using a unique model "reverse startup" approach. This includes Nanotechnology & Material Sciences, Life Sciences (Pharma, Device, Diagnostics, Research, OTC/CPG), ICT (High-performance computing, Web 2.0, Machine Learning, Pattern Recognition/Dynamic Scaffolding, Virtualization platforms, Simulation, Physics Engines, and New Media), and lastly Clean/Green Tech (Solar, Wind, Smart Software, Materials, renewable Energy, non-food stock biofuels & ISBEs).
Neil has capital market experience from seed to IPO with over $420M directly raised and involved in roadshow teams for IPOs totaling > $1B. He is on the Investment Committee for Genomic Medicine Catalyst Investment Fund, UK. He is a scholar-practitioner, author, and speaker on innovation, entrepreneurship, and capital appreciation methods for science & technology commercialization. Neil received his doctorate from University of Liverpool, UK and MBA & MS from Webster.
Board Member, Aequs Consumer
Head India, Inflexion
Rohit has spent several years in three continents building portfolio companies of Private Equity Firms, a large engineering company, and a technology firm. Rohit ran his own auto components business Adeep Group in India sold to Actis Private Equity in 2006. At the time of sale, Adeep was a $25M company with 1300 employees in the business of manufacturing locksets, wheel rims, clutch assemblies & fuel taps.
Between 1993 and 1998 Rohit managed Hewlett Packard's Medical Supplies Manufacturing business in Andover, MA, USA. From 1983 to 1992 Rohit managed the manufacturing activities of Scully Signal Company manufacturing heating oil delivery systems in Wilmington, MA. He is well-connected and highly experienced in helping European and British companies develop their operations in India. He delivers targeted market development plans to support portfolio company activities in India and helps with investment team decisions. Currently a Member of the board and an investor in Aequs Consumer, a subsidiary of Aegus Global.
Rohit has an MBA from Northeastern University, Boston, an MS in Industrial Engineering from Texas Tech University, and a BS in Mechanical Engineering from Anna University, Chennai. Rohit is passionate about the opportunities India offers to ambitious companies however when not at work he enjoys swimming and basketball and is a fiercely competitive tennis player.
Barrister at Law,ex-Group Legal Counsel
Airtel & Zain
Parwez is ex-Group Legal Counsel for Airtel Africa that acquired assets of Zain Telecom in Africa who pursued law at the University of Mauritius and is a barrister of the Bar of Mauritius. He was a pupil of Lord Marks QC of the Inner Temple, England, and of Nicolas Sorensen of the Barreau d’Aix-en-Provence, France.
He is an expert in the telecommunications industry and has earned valuable experience for 30+ years, as a legal adviser to large telecom multi-nationals and in this capacity, he participated in numerous bids for telecoms licenses worldwide and was part of M&A teams during major transactions in those telecom groups. He was the ex-CEO of MADACOM, Madagascar, (now Airtel) where he helmed the company into a USD 100MN successful business prior to selling the company to Zain. A seasoned team leader, he has served with teams of PWC and he served was the ex-legal counsel with Celtel, and Zain (MTC group). He has acted as a legal advisor to the Distacom Group that owned Orange (now PCCW) in Hong Kong, Spice Telecom in India, and MADACOM S.A. in Madagascar. Parwez advised GSM license bids in Ivory Coast, DRC, Mayotte, Comoros, Anjouan, Mauritius, South Africa, and Lebanon. Until recently he was recently a team member at Benoit Chambers, a leading law firm in Mauritius.
He has an advanced Management course from London Business School. Parwez is excellent in English and French.
C. Richard Piazza
Chairman, Qsam Pharmaceuticals
C. Richard Piazza, Ph.D. is a seasoned healthcare executive with 48 years of global experience in the medical device, biotech, and pharma. His 44 years in general management positions encompass business growth & adoption, spearheading M&A, JV, Board experience in both public (NASDAQ, AMEX, TSX, DAX, TASE, FWB) and private companies including Ohmeda (BOC, now Linde Group), Smith & Nephew Pharma, Marquest & VitaGen (world’s first bioartificial liver). He has an invaluable drug, biologic, device development & clinical trial experience, regulatory approvals for levels of products- Class I, II & III devices, BLA, NDA & ANDAs with clinical sites included both domestic and international sites.Richard, highly regarded in TMC is an industry representative working with the FDA and Congress to craft the FDA Modernization Act for Medical Devices and served on industry association boards & committees (Advamed, Biocomm, Bio Houston). In addition to industry affiliations, Richard remains committed to working with well-known medical pioneers, “world-class,” teams, and to identify, and advance new technologies to bring them to fruition. He acts as an advisor to some of the world’s leading institutions such as MD Anderson Cancer Center, Baylor College of Medicine, University of California San Diego, University of Chicago & Kings College Hospital (London.) Richard has been a Guest Lecturer in Sales & Marketing strategy at numerous Universities including Rice University School of Management, UCLA, University of Wisconsin, CAL Tech-MIT forum, University of British Columbia & University of California San Diego. In 2019 he co-founded QSAM Therapeutics, Inc. with Doug Baum and currently serves as its Executive Chairman.